Bioanalytical and biophysical techniques for the elucidation of the mode of action of metal-based drugs

Current Topics in Medicinal Chemistry

Volumn 11, Issue 21, 2011, Pages 2632-2646

  Groessl, Michael ^a   Dyson, Paul J ^a  

^a EPFL   (Switzerland)

Author keywords

Anticancer; Bioanalytical chemistry; Metal based drugs; Mode of action; Review

Indexed keywords

ANTINEOPLASTIC AGENT; AURANOFIN; CARBOPLATIN; CISPLATIN; GALLIUM; GLUTATHIONE TRANSFERASE; GOLD; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; OXALIPLATIN; RUTHENIUM; SM 54111; TITANIUM; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; BIOACCUMULATION; BREAST CANCER; CANCER CHEMOTHERAPY; CIRCULAR DICHROISM; DENSITY FUNCTIONAL THEORY; DRUG MECHANISM; FLUORESCENCE MICROSCOPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OSTEOSARCOMA; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; CHEMISTRY TECHNIQUES, ANALYTICAL; DNA; DRUG DELIVERY SYSTEMS; GALLIUM; GOLD; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; PROTEINS; RUTHENIUM; TITANIUM;

EID: 80055076407     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798040705     Document Type: Review

References (158)

1. Magner, L. N. A history of medicine. M. Dekker: New York, 1992; p xvi, 393 p.
2. nd ed.; Academic: Amsterdam; London, 2003; p xiv, 768 p.
3. Lippert, B. Cisplatin. Chemistry and biochemistry of a leading anticancer drug. VHCA: Zürich, 1999; p 605.
4. Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P. J. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem., 2006, 45 (22), 9006-9013.
5. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7 (8), 573-584.
6. Ott, I.; Gust, R. Non platinum metal complexes as anti-cancer drugs. Arch. Pharm., 2007, 340 (3), 117-126.
7. Shaw, C. F. Gold-based therapeutic agents. Chem. Rev., 1999, 99 (9), 2589-2600.
8. Atiyeh, B. S.; Costagliola, M.; Hayek, S. N.; Dibo, S. A. Effect of silver on burn wound infection control and healing: Review of the literature. Burns, 2007, 33 (2), 139-148.
9. Sharma, V.; Piwnica-Worms, D. Metal complexes for therapy and diagnosis of drug resistance. Chem. Rev., 1999, 99 (9), 2545-2560.
10. Wong, F. C.; Kim, E. E. A review of molecular imaging studies reaching the clinical stage. Eur. J. Rad., 2009, 70 (2), 205-211.
11. Gill, M. R.; Garcia-Lara, J.; Foster, S. J.; Smythe, C.; Battaglia, G.; Thomas, J. A. A ruthenium(II) polypyridyl complex for direct imaging of DNA structure in living cells. Nat. Chem., 2009, 1(8), 662-667.
12. Zava, O.; Zakeeruddin, S. M.; Danelon, C.; Vogel, H.; Gratzel, M.; Dyson, P. J. A cytotoxic ruthenium tris(bipyridyl) complex that accumulates at plasma membranes. ChemBioChem, 2009, 10 (11), 1796-1800.
13. Liang, X. J.; Shen, D. W.; Chen, K. G.; Wincovitch, S. M.; Garfield, S. H.; Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. J. Cell Physiol., 2005, 202 (3), 635-641.
14. Safaei, R.; Katano, K.; Larson, B. J.; Samimi, G.; Holzer, A. K.; Naerdemann, W.; Tomioka, M.; Goodman, M.; Howell, S. B. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin. Cancer Res., 2005, 11 (2), 756-767.
15. Safaei, R.; Larson, B. J.; Cheng, T. C.; Gibson, M. A.; Otani, S.; Naerdemann, W.; Howell, S. B. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther., 2005, 4 (10), 1595-1604.
16. Katano, K.; Safaei, R.; Samimi, G.; Holzer, A.; Tomioka, M.; Goodman, M.; Howell, S. B., Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin. Cancer Res., 2004, 10 (13), 4578-4588.
17. Chauhan, S. S.; Liang, X. J.; Su, A. W.; Pai-Panandiker, A.; Shen, D. W.; Hanover, J. A.; Gottesman, M. M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br. J. Cancer, 2003, 88 (8), 1327-1334.
18. Alderden, R. A.; Mellor, H. R.; Modok, S.; Hambley, T. W.; Callaghan, R. Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochem. Pharmacol., 2006, 71 (8), 1136-1145.
19. Ohndorf, U. M.; Rould, M. A.; He, Q.; Pabo, C. O.; Lippard, S. J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature, 1999, 399 (6737), 708-712.
20. Ang, Wee H.; Parker, Lorien J.; De Luca, A.; Juillerat-Jeanneret, L.; Morton, Craig J.; Lo Bello, M.; Parker, Michael W.; Dyson, Paul J. Rational design of an organometallic glutathione transferase inhibitor. Angew. Chem. Int. Ed., 2009, 48 (21), 3854-3857.
21. Casini, A.; Guerri, A.; Gabbiani, C.; Messori, L. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. J. Inorg. Biochem., 2008, 102 (5-6), 995-1006.
22. Chen, K. G.; Valencia, J. C.; Lai, B.; Zhang, G.; Paterson, J. K.; Rouzaud, F.; Berens, W.; Wincovitch, S. M.; Garfield, S. H.; Leapman, R. D.; Hearing, V. J.; Gottesman, M. M. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc. Natl. Acad. Sci. USA, 2006, 103 (26), 9903-9907.
23. Shimura, M.; Saito, A.; Matsuyama, S.; Sakuma, T.; Terui, Y.; Ueno, K.; Yumoto, H.; Yamauchi, K.; Yamamura, K.; Mimura, H.; Sano, Y.; Yabashi, M.; Tamasaku, K.; Nishio, K.; Nishino, Y.; Endo, K.; Hatake, K.; Mori, Y.; Ishizaka, Y.; Ishikawa, T., Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment. Cancer Res., 2005, 65 (12), 4998-5002.
24. Waern, J. B.; Harris, H. H.; Lai, B.; Cai, Z. H.; Harding, M. M.; Dillon, C. T., Intracellular mapping of the distribution of metals derived from the antitumor metallocenes. J. Biol. Inorg. Chem., 2005, 10 (5), 443-452.
25. Bonnitcha, P. D.; Hall, M. D.; Underwood, C. K.; Foran, G. J.; Zhang, M.; Beale, P. J.; Hambley, T. W., XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes. J. Inorg. Biochem., 2006, 100 (5-6), 963-971.
26. Hall, M. D.; Alderden, R. A.; Zhang, M.; Beale, P. J.; Cai, Z.; Lai, B.; Stampfl, A. P.; Hambley, T. W. The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours. J. Struct. Biol., 2006, 155 (1), 38-44.
27. Hall, M. D.; Dillon, C. T.; Zhang, M.; Beale, P.; Cai, Z.; Lai, B.; Stampfl, A. P.; Hambley, T. W. The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells. J. Biol. Inorg. Chem., 2003, 8 (7), 726-732.
28. Jackson-Rosario, S.; Cowart, D.; Myers, A.; Tarrien, R.; Levine, R. L.; Scott, R. A.; Self, W. T. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J. Biol. Inorg. Chem., 2009, 14 (4), 507-519.
29. Andrushchenko, V.; Tsankov, D.; Wieser, H., Vibrational circular dichroism spectroscopy and the effects of metal ions on DNA structure. J. Mol. Struct., 2003, 661-662, 541-560.
30. Casini, A.; Messori, L.; Orioli, P.; Gielen, M.; Kemmer, M.; Willem, R. Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. J. Inorg. Biochem., 2001, 85 (4), 297-300.
31. Malina, J.; Novakova, O.; Keppler, B. K.; Alessio, E.; Brabec, V. Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(lll) in cell-free media. J. Biol. Inorg. Chem., 2001, 6 (4), 435-445.
32. Messori, L.; Orioli, P.; Tempi, C.; Marcon, G. Interactions of selected gold(III) complexes with calf thymus DNA. Bioch. Biophysi. Res. Commun., 2001, 281 (2), 352-360.
33. Ivanov, A. I.; Christodoulou, J.; Parkinson, J. A.; Barnham, K. J.; Tucker, A.; Woodrow, J.; Sadler, P. J. Cisplatin binding sites on human albumin. J. Biol. Chem., 1998, 273 (24), 14721-14730.
34. Cox, M. C.; Barnham, K. J.; Frenkiel, T. A.; Hoeschele, J. D.; Mason, A. B.; He, Q. Y.; Woodworth, R. C.; Sadler, P. J. Identification of platination sites on human serum transferrin using C-13 and N-15 NMR spectroscopy. J. Biol. Inorg. Chem., 1999, 4 (5), 621-631.
35. Cubo, L.; Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Jimenez-Barbero, J.; Navarro-Ranninger, C.; Quiroga, A. G. Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands. Chem. Eur. J., 2009, 15 (36), 9139-9146.
36. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Biochemistry, 2007, 46 (43), 12220-12230.
37. Esteban-Fernandez, D.; Verdaguer, J. M.; Ramirez-Camacho, R.; Palacios, M. A.; Gomez-Gomez, M. M. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J. Anal. Toxicol., 2008, 32 (2), 140-146.
38. Egger, A. E.; Rappel, C.; Jakupec, M. A.; Hartinger, C. G.; Heffeter, P.; Keppler, B. K. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J. Anal. At. Spectrom., 2009, 24 (1), 51-61.
39. Chen, H.; Ahn, R.; Van den Bossche, J.; Thompson, D. H.; O'Halloran, T. V. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther., 2009, 8 (7), 1955-1963.
40. Chen, H.; Pazicni, S.; Krett, N. L.; Ahn, R. W.; Penner-Hahn, J. E.; Rosen, S. T.; O'Halloran, T. V. Coencapsulation of arsenic-and platinum-based drugs for targeted cancer treatment. Angew. Chem. Int. Ed., 2009, 48 (49), 9295-9299.
41. Xing, R.; Wang, X.; Zhang, C.; Zhang, Y.; Wang, Q.; Yang, Z.; Guo, Z. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J. Inorg. Biochem., 2009, 103 (7), 1039-44.
42. Ramirez-Camacho, R.; Fernandez, D. E.; Verdaguer, J. M.; Gomez, M. M. G.; Trinidad, A.; Garcia-Berrocal, J. R.; Corvillo, M. A. P. Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration. Acta Otolaryngol., 2008, 128 (5), 505-509.
43. Brouwers, E. E.; Tibben, M.; Rosing, H.; Schellens, J. H.; Beijnen, J. H. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom. Rev., 2008, 27 (2), 67-100.
44. Hartinger, C. G.; Tsybin, Y. O.; Fuchser, J.; Dyson, P. J. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. Inorg. Chem., 2008, 47 (1), 17-19.
45. Moreno-Gordaliza, E.; Canas, B.; Palacios, M. A.; Gomez-Gomez, M. M. Top-down mass spectrometric approach for the full characterization of insulin-cisplatin adducts. Anal. Chem., 2009, 81 (9), 3507-3516.
46. Egger, A. E.; Hartinger, C. G.; Ben Hamidane, H.; Tsybin, Y. O.; Keppler, B. K.; Dyson, P. J., High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. Inorg. Chem., 2008, 47 (22), 10626-10633.
47. Groessl, M.; Tsybin, Y. O.; Hartinger, C. G.; Keppler, B. K.; Dyson, P. J. Ruthenium versus platinum: Interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation-mass spectrometry. J. Biol. Inorg. Chem., 2010, 15(5),677-688.
48. Nyakas, A.; Eymann, M.; Schurch, S. The influence of Cisplatin on the gas-phase dissociation of oligonucleotides studied by electrospray ionization tandem mass spectrometry. J. Am. Soc. Mass Spectrom., 2009, 20 (5), 792-804.
49. Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.; Dyson, P. J. Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. J. Anal. At. Spectrom., 2007, 22 (8), 960-967.
50. Ang, W. H.; Daldini, E.; Juillerat-Jeanneret, L.; Dyson, P. J. Strategy To Tether Organometallic Ruthenium-Arene Anticancer Compounds to Recombinant Human Serum Albumin. Inorg. Chem., 2007, 46 (22), 9048-9050.
51. Allardyce, C. S.; Dyson, P. J.; Coffey, J.; Johnson, N. Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin. Rapid Commun. Mass Spectrom., 2002, 16 (10), 933-5.
52. Will, J.; Kyas, A.; Sheldrick, W. S.; Wolters, D., Identification of (eta6-arene)ruthenium(II) protein binding sites in E. coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta6-p-cymene)RuCl2 (DMSO)] to stress-regulated proteins and to helicases. J. Biol. Inorg. Chem., 2007, 12 (6), 883-94.
53. Will, J.; Sheldrick, W. S.; Wolters, D., Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry. J. Biol. Inorg. Chem., 2008, 13 (3), 421-34.
54. Will, J.; Wolters, D. A.; Sheldrick, W. S., Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry. Chemmedchem, 2008, 3 (11), 1696-707.
55. Groessl, M.; Hartinger, C. G.; Dyson, P. J.; Keppler, B. K. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem., 2008, 102 (5-6), 1060-1065.
56. Sulyok, M.; Hann, S.; Hartinger, C. G.; Keppler, B. K.; Stingeder, G.; Koellensperger, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J. Anal. At. Spectrom, 2005, 20 (9), 856-863.
57. Shimomura, O. Discovery of Green Fluorescent Protein (GFP) (Nobel Lecture)13. Angew. Chem. Int. Ed., 2009, 48 (31), 5590-5602.
58. Domaille, D. W.; Que, E. L.; Chang, C. J. Synthetic fluorescent sensors for studying the cell biology of metals. Nat. Chem. Biol., 2008, 4 (3), 168-75.
59. Montgomery, C. P.; Murray, B. S.; New, E. J.; Pal, R.; Parker, D. Cell-Penetrating Metal Complex Optical Probes: Targeted and Responsive Systems Based on Lanthanide Luminescence. Acc. Chem. Res., 2009, 42 (7), 925-937.
60. Klein, A. V.; Hambley, T. W. Platinum drug distribution in cancer cells and tumors. Chem. Rev., 2009, 109 (10), 4911-20.
61. Molenaar, C.; Teuben, J. M.; Heetebrij, R. J.; Tanke, H. J.; Reedijk, J. New insights in the cellular processing of platinum antitumor compounds, using fluorophore-labeled platinum complexes and digital fluorescence microscopy. J. Biol. Inorg. Chem., 2000, 5 (5), 655-65.
62. Hall, M. D.; Okabe, M.; Shen, D. W.; Liang, X. J.; Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 495-535.
63. Alonso, A.; Almendral, M. J.; Curto, Y.; Criado, J. J.; Rodriguez, E.; Manzano, J. L. New fluorescent antitumour cisplatin analogue complexes. Study of the characteristics of their binding to DNA by flow injection analysis. J. Fluoresc., 2007, 17 (4), 390-400.
64. Vock, C. A.; Ang, W. H.; Scolaro, C.; Phillips, A. D.; Lagopoulos, L.; Juillerat-Jeanneret, L.; Sava, G.; Scopelliti, R.; Dyson, P. J. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J. Med. Chem., 2007, 50 (9), 2166-2175.
65. Yamamoto, N.; Danos, S.; Bonnitcha, P. D.; Failes, T. W.; New, E. J.; Hambley, T. W. Cellular uptake and distribution of cobalt complexes of fluorescent ligands. J. Biol. Inorg. Chem., 2008, 13 (6), 861-871.
66. Lau, J. S.; Lee, P. K.; Tsang, K. H.; Ng, C. H.; Lam, Y. W.; Cheng, S. H.; Lo, K. K. Luminescent cyclometalated iridium(III) polypyridine indole complexes--synthesis, photophysics, electrochemistry, protein-binding properties, cytotoxicity, and cellular uptake. Inorg. Chem., 2009, 48 (2), 708-718.
67. Whan, R. M.; Messerle, B. A.; Hambley, T. W. Binding of [Pt(1C3)(dien)](2+) to the duplex DNA oligonucleotide 5'-d(TGGCCA)-3': the effect of an appended positive charge on the orientation and location of anthraquinone intercalation. Dalton Trans., 2009, (6), 932-939.
68. Kalayda, G. V.; Jansen, B. A.; Molenaar, C.; Wielaard, P.; Tanke, H. J.; Reedijk, J. Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance. J. Biol. Inorg. Chem., 2004, 9 (4), 414-422.
69. Jansen, B. A.; Wielaard, P.; Kalayda, G. V.; Ferrari, M.; Molenaar, C.; Tanke, H. J.; Brouwer, J.; Reedijk, J. Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells. J. Biol. Inorg. Chem., 2004, 9 (4), 403-413.
70. Schmitt, F.; Govindaswamy, P.; Suss-Fink, G.; Ang, W. H.; Dyson, P. J.; Juillerat-Jeanneret, L.; Therrien, B. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J. Med. Chem. 2008, 51 (6), 1811-1816.
71. Schmitt, F.; Govindaswamy, P.; Zava, O.; Suss-Fink, G.; Juillerat-Jeanneret, L.; Therrien, B. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J. Biol. Inorg. Chem., 2009, 14 (1), 101-109.
72. Zava, O.; Mattsson, J.; Therrien, B.; Dyson, Paul J. Evidence for drug release from a metalla-cage delivery vector following cellular internalisation. Chem. Eur. J., 2009, 16(5), 1428-1431.
73. Levina, A.; Armstrong, R. S.; Lay, P. A. Three-dimensional structure determination using multiple-scattering analysis of XAFS: applications to metalloproteins and coordination chemistry. Coord. Chem. Rev., 2005, 249 (1-2), 141-160.
74. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1 (6), 458-470.
75. Janssens, K., X-ray based methods of analysis. In: Non-destructive microanalysis of cultural heritage materials, Janssens, K.; Van Grieken, R., Eds. Elsevier B.V. Amsterdam, 2004; Vol. XLII, pp 129-226.
76. Fahrni, C. J. Biological applications of X-ray fluorescence microscopy: exploring the subcellular topography and speciation of transition metals. Curr. Opin. Chem. Biol., 2007, 11 (2), 121-127.
77. Ralle, M.; Lutsenko, S. Quantitative imaging of metals in tissues. Biometals, 2009, 22 (1), 197-205.
78. Ascone, I.; Strange, R. Biological X-ray absorption spectroscopy and metalloproteomics. J. Synchrotron. Radiat., 2009, 16 (Pt 3), 413-421.
79. Lobinski, R.; Moulin, C.; Ortega, R. Imaging and speciation of trace elements in biological environment. Biochimie, 2006, 88 (11), 1591-1604.
80. McRae, R.; Bagchi, P.; Sumalekshmy, S.; Fahrni, C. J. In situ imaging of metals in cells and tissues. Chem. Rev., 2009, 109 (10), 4780-4827.
81. Ortega, R.; Deves, G.; Carmona, A., Bio-metals imaging and speciation in cells using proton and synchrotron radiation X-ray microspectroscopy. J. R. Soc. Interface, 2009, 6 (Suppl 5), S649-658.
82. Ang, W. H.; Pilet, S.; Scopelliti, R.; Bussy, F.; Juillerat-Jeanneret, L.; Dyson, P. J. Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J. Med. Chem., 2005, 48 (25), 8060-8069.
83. Sriskandakumar, T.; Petzold, H.; Bruijnincx, P. C.; Habtemariam, A.; Sadler, P. J.; Kennepohl, P. Influence of oxygenation on the reactivity of ruthenium-thiolato bonds in arene anticancer complexes: insights from XAS and DFT. J. Am. Chem. Soc., 2009, 131 (37), 13355-13361.
84. Ascone, I.; Messori, L.; Casini, A.; Gabbiani, C.; Balerna, A.; Dell'Unto, F.; Castellano, A. C. Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)] [ImH] (Im = imidazole) to bovine serum albumin. Inorg. Chem., 2008, 47 (19), 8629-8634.
85. Harris, T. V.; Szilagyi, R. K.; McFarlane Holman, K. L. Electronic structural investigations of ruthenium compounds and anticancer prodrugs. J. Biol. Inorg. Chem., 2009, 14 (6), 891-898.
86. Arcon, I.; Kodre, A.; Abra, R. M.; Huang, A.; Vallner, J. J.; Lasic, D. D. EXAFS study of liposome-encapsulated cisplatin. Colloids Surf. B., 2004, 33 (3-4), 199-204.
87. Jalilehvand, F.; Laffin, L. J. Structure of the hydrated platinum(II) ion and the cis-diammineplatinum(II) complex in acidic aqueous solution: An EXAFS study. Inorg. Chem., 2008, 47 (8), 3248-3254.
88. Provost, K.; Bouvet-Muller, D.; Crauste-Manciet, S.; Moscovici, J.; Olivi, L.; Vlaic, G.; Michalowicz, A. EXAFS structural study of platinum-based anticancer drugs degradation in presence of sulfur nucleophilic species. Biochimie, 2009, 91 (10), 1301-1306.
89. Bouvet, D.; Michalowicz, A.; Crauste-Manciet, S.; Curis, E.; Nicolis, I.; Olivi, L.; Vlaic, G.; Brossard, D.; Provost, K. EXAFS characterization of oxaliplatin anticancer drug and its degradation in chloride media. J. Synchrotron. Radiat., 2006, 13 (Pt 6), 477-483.
90. Beret, E. C.; Provost, K.; Muller, D.; Marcos, E. S. Coupling CP-MD simulations and x-ray absorption spectroscopy: exploring the structure of oxaliplatin in aqueous solution. J. Phys. Chem. B, 2009, 113 (36), 12343-12352.
91. Aliaga-Alcalde, N.; George, S. D.; Alfaro-Fuentes, I.; Cooper, G. J. T.; Barba-Behrens, N.; Bernes, S.; Reedijk, J. Physical characterization and biological studies of a (streptidine)((PtCl4)-Cl-II) compound. Polyhedron, 2009, 28 (16), 3459-3466.
92. George, S. D.; Brant, P.; Solomon, E. I. Metal and ligand K-Edge XAS of organotitanium complexes: Metal 4p and 3d contributions to pre-edge intensity and their contributions to bonding. J. Am. Chem. Soc., 2005, 127 (2), 667-674.
93. Hofer, T. S.; Randolf, B. R.; Shah, S. A. A.; Rode, B. M.; Persson, I. Structure and dynamics of the hydrated palladium(II) ion in aqueous solution A QMCF MD simulation and EXAFS spectroscopic study. Chem. Phys. Lett., 2007, 445 (4-6), 193-197.
94. nd ed.; Wiley-VCH: New York, 2000; p xix, 877 p.
95. Esteban-Fernandez, D.; Moreno-Gordaliza, E.; Canas, B.; Palacios, M. A.; Milagros Gomez-Gomez, M. Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. Metallomics, 2010, 2 (1), 19-38.
96. Trynda-Lemiesz, L.; Karaczyn, A.; Keppler, B. K.; Kozlowski, H. Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III). J. Inorg. Biochem., 2000, 78 (4), 341-346.
97. Trynda-Lemiesz, L.; Keppler, B. K.; Kozlowski, H. Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis (imidazol) ruthenate(III)]. J. Inorg. Biochem., 1999, 73 (3), 123-128.
98. Trynda-Lemiesz, L.; Kozlowski, H.; Keppler, B. K. Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin. J. Inorg. Biochem., 1999, 77 (3-4), 141-146.
99. Ronconi, L.; Sadler, P. J. Applications of heteronuclear NMR spectroscopy in biological and medicinal inorganic chemistry. Coord. Chem. Rev., 2008, 252 (21-22), 2239-2277.
100. Berners-Price, S. J.; Ronconi, L.; Sadler, P. J. Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy. Prog. Nucl. Magn. Res. Spectrosc., 2006, 49 (1), 65-98.
101. Gelasco, A.; Lippard, S. J. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry, 1998, 37 (26), 9230-9239.
102. Bancroft, D. P.; Lepre, C. A.; Lippard, S. J. Pt-195 NMR Kinetic and Mechanistic Studies of Cis-Diamminedichloroplatinum and Trans-Diamminedichloroplatinum(II) Binding to DNA. J. Am. Chem. Soc., 1990, 112 (19), 6860-6871.
103. Kasherman, Y.; Sturup, S.; Gibson, D. Is glutathione the major cellular target of cisplatin? a study of the interactions of cisplatin with cancer cell extracts. J. Med. Chem., 2009, 52 (14), 4319-4328.
104. Kang, M.; Chifotides, H. T.; Dunbar, K. R. 2D NMR study of the DNA duplex d(CTCTC*A*ACTTCC)center dot d(GGAAGTTGAGAG) cross-linked by the antitumor-active Dirhodium(II,II) unit at the cytosine-adenine step. Biochemistry, 2008, 47 (8), 2265-2276.
105. Wang, F. Y.; Xu, J. J.; Habtemariam, A.; Bella, J.; Sadler, P. J. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: Detection of a sulfenato intermediate. J. Am. Chem. Soc., 2005, 127 (50), 17734-17743.
106. Wang, F. Y.; Bella, J.; Parkinson, J. A.; Sadler, P. J. Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide. J. Biol. Inorg. Chem., 2005, 10 (2), 147-155.
107. Liu, H. K.; Wang, F. Y.; Parkinson, J. A.; Bella, J.; Sadler, P. J. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes. Chem. Eur. J., 2006, 12 (23), 6151-6165.
108. Su, Q.; Liu, Q.; Luo, G.; Liu, W.; Yu, Y.; Wang, Y.; Bi, K. Pharmacokinetic investigation on a novel antitumour platinum compound in rabbit plasma by inductively coupled plasma mass spectrometry after intravenous administration. Drug Dev. Ind. Pharm., 2008, 34 (5), 472-477.
109. Henke, M. M.; Richly, H.; Drescher, A.; Grubert, M.; Alex, D.; Thyssen, D.; Jaehde, U.; Scheulen, M. E.; Hilger, R. A., Pharmacokinetic study of sodium trans [tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors. Int. J. Clin. Pharmacol. Ther., 2009, 47 (1), 58-60.
110. Lentz, F.; Drescher, A.; Lindauer, A.; Henke, M.; Hilger, R. A.; Hartinger, C. G.; Scheulen, M. E.; Dittrich, C.; Keppler, B. K.; Jaehde, U.; Re, C. E. S. A. D. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anti-Cancer Drugs, 2009, 20 (2), 97-103.
111. Iannitti-Tito, P.; Weimann, A.; Wickham, G.; Sheil, M. M. Structural analysis of drug-DNA adducts by tandem mass spectrometry. Analyst, 2000, 125 (4), 627-633.
112. Beck, J. L.; Colgrave, M. L.; Ralph, S. F.; Sheil, M. M., Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom. Rev., 2001, 20 (2), 61-87.
113. Zhao, T.; King, F. L. Direct determination of the primary binding site of cisplatin on cytochrome c by mass spectrometry. J. Am. Soc. Mass Spectrom., 2009, 20 (6), 1141-1147.
114. Casini, A.; Mastrobuoni, G.; Terenghi, M.; Gabbiani, C.; Monzani, E.; Moneti, G.; Casella, L.; Messori, L., Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. J. Biol. Inorg. Chem., 2007, 12 (8), 1107-1117.
115. Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Moneti, G.; Dyson, P. J.; Messori, L., Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J. Biol. Inorg. Chem., 2009, 14 (5), 761-770.
116. Casini, A.; Mastrobuoni, G.; Ang, W. H.; Gabbiani, C.; Pieraccini, G.; Moneti, G.; Dyson, P. J.; Messori, L. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. Chemmedchem, 2007, 2 (5), 631-635.
117. Gabbiani, C.; Casini, A.; Mastrobuoni, G.; Kirshenbaum, N.; Moshel, O.; Pieraccini, G.; Moneti, G.; Messori, L.; Gibson, D. Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. J. Biol. Inorg. Chem., 2008, 13 (5), 755-764.
118. Hartinger, C. G.; Casini, A.; Duhot, C.; Tsybin, Y. O.; Messori, L.; Dyson, P. J. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity. J. Inorg. Biochem., 2008, 102 (12), 2136-2141.
119. Casini, A.; Karotki, A.; Gabbiani, C.; Rugi, F.; Vasak, M.; Messori, L.; Dyson, P. J. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. Metallomics, 2009, 1 (5), 434-441.
120. Cubo, L.; Groessl, M.; Casini, A.; Dyson, P. J.; Quiroga, A. G.; Navarro-Ranninger, C. Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands. Chemmedchem 2010, 5(8), 1335-1343.
121. Gonnet, F.; Kocher, F.; Blais, J. C.; Bolbach, G.; Tabet, J. C.; Chottard, J. C. Kinetic analysis of the reaction between d(TTGGCCAA) and [Pt(NH3)3(H2O)]2+ by enzymatic degradation of the products and ESI and MALDI mass spectrometries. J. Mass Spectrom., 1996, 31 (7), 802-809.
122. Chifotides, H. T.; Koomen, J. M.; Kang, M.; Tichy, S. E.; Dunbar, K. R.; Russell, D. H. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry. Inorg. Chem., 2004, 43 (20), 6177-6187.
123. Zhu, J.; Zhao, Y.; Zhu, Y.; Wu, Z.; Lin, M.; He, W.; Wang, Y.; Chen, G.; Dong, L.; Zhang, J.; Lu, Y.; Guo, Z. DNA cross-linking patterns induced by an antitumor-active trinuclear platinum complex and comparison with its dinuclear analogue. Chemistry, 2009, 15 (21), 5245-5253.
124. Koomen, J. M.; Ruotolo, B. T.; Gillig, K. J.; McLean, J. A.; Russell, D. H.; Kang, M.; Dunbar, K. R.; Fuhrer, K.; Gonin, M.; Schultz, J. A. Oligonucleotide analysis with MALDI-ion-mobility-TOFMS. Anal. Bioanal. Chem., 2002, 373 (7), 612-617.
125. Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P. J. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem., 2006, 45 (22), 9006-9013.
126. Hartinger, C. G.; Keppler, B. K., CE in anticancer metallodrug research-an update. Electrophoresis, 2007, 28 (19), 3436-3446.
127. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106 (6), 2224-2248.
128. Szpunar, J. Advances in analytical methodology for bioinorganic speciation analysis: metallomics, metalloproteomics and heteroatom-tagged proteomics and metabolomics. Analyst, 2005, 130 (4), 442-465.
129. Michalke, B. Capillary electrophoresis-inductively coupled plasma-mass spectrometry: a report on technical principles and problem solutions, potential, and limitations of this technology as well as on examples of application. Electrophoresis, 2005, 26 (7-8), 1584-1597.
130. Lobinski, R.; Schaumlöffel, D.; Szpunar, J. Mass spectrometry in bioinorganic analytical chemistry. Mass Spec. Rev., 2006, 25 (2), 255-289.
131. Groessl, M.; Hartinger, C. G.; Dyson, P. J.; Keppler, B. K. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem., 2008, 102 (5-6), 1060-1065.
132. Bytzek, A. K.; Reithofer, M. R.; Galanski, M.; Groessl, M.; Keppler, B. K.; Hartinger, C. G. The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes. Electrophoresis, 2010, 31 (7), 1144-1150.
133. Michalke, B. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs. J. Trace Elements Med. Biol.,2010, 24 (2), 69-77.
134. Hann, S.; Koellensperger, G.; Stefanka, Z.; Stingeder, G.; Furhacker, M.; Buchberger, W.; Mader, R. M. Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine. J. Analyt. Atomic Spectrom., 2003, 18 (11), 1391-1395.
135. Koellensperger, G.; Stefanka, Z.; Meelich, K.; Galanski, M.; Keppler, B. K.; Stingeder, G.; Hann, S., Species specific IDMS for accurate quantification of carboplatin in urine by LC-ESI-TOFMS and LC-ICP-QMS. J. Analyt. Atomic Spectrom., 2008, 23 (1), 29-36.
136. Hamdan, M.; Galvani, M.; Righetti, P. G. Monitoring 2-D gel-induced modifications of proteins by MALDI-TOF mass spectrometry. Mass Spec. Rev., 2001, 20 (3), 121-141.
137. Allardyce, C. S.; Dyson, P. J.; Abou-Shakra, F. R.; Birtwistle, H.; Coffey, J. Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systems. Chem. Commun., 2001, (24), 2708-2709.
138. Khalaila, I.; Bergamo, A.; Bussy, F.; Sava, G.; Dyson, P. J. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int. J. Oncol., 2006, 29 (1), 261-268.
139. 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotech., 2001, 19 (3), 242-247.
140. Esteban-Fernandez, D.; Montes-Bayon, M.; Gonzalez, E. B.; Gomez, M. M. G.; Palacios, M. A.; Sanz-Medel, A. Atomic (HPLC-ICP-MS) and molecular mass spectrometry (ESI-Q-TOF) to study cis-platin interactions with serum proteins. J. Anal. At. Spectrom., 2008, 23 (3), 378-384.
141. Groessl, M.; Terenghi, M.; Casini, A.; Elviri, L.; Lobinski, R.; Dyson, P. J. Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatoghraphy-ICP-MS and ESI-MS. J. Anal. At. Spectrom., 2010, 25(3),305-313.
142. Garcia Sar, D.; Montes-Bayon, M.; Blanco Gonzalez, E.; Sierra, L. M.; Aguado, L.; Comendador, M. A.; Koellensperger, G.; Hann, S.; Sanz-Medel, A. Quantitative profiling of in vivo generated cisplatin-dna adducts using different isotope dilution strategies. Anal. Chem. 2009, 81 (23), 9553-60.
143. Groessl, M.; Bytzek, A.; Hartinger, C. G. The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques. Electrophoresis 2009, 30 (15), 2720-2727.
144. Polec-Pawlak, K.; Abramski, J. K.; Semenova, O.; Hartinger, C. G.; Timerbaev, A. R.; Keppler, B. K.; Jarosz, M. Platinum group metallodrug-protein binding studies by capillary electrophoresis -inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis, 2006, 27 (5-6), 1128-1135.
145. Timerbaev, A. R.; Aleksenko, S. S.; Polec-Pawlak, K.; Ruzik, R.; Semenova, O.; Hartinger, C. G.; Oszwaldowski, S.; Galanski, M.; Jarosz, M.; Keppler, B. K. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Electrophoresis, 2004, 25 (13), 1988-1995.
146. Bytzek, A. K.; Enyedy, É. A.; Kiss, T.; Keppler, B. K.; Hartinger, C. G. Biodistribution of anti-diabetic Zn(II) complexes in human serum and in vitro protein-binding studies by means of CZE-ICP-MS. Electrophoresis, 2009, 30 (23), 4075-4082.
147. Vessieres, A.; Top, S.; Beck, W.; Hillard, E.; Jaouen, G. Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans, 2006, (4), 529-541.
148. Ang, W. H.; Khalaila, I.; Allardyce, C. S.; Juillerat-Jeanneret, L.; Dyson, P. J. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc., 2005, 127 (5), 1382-1383.
149. Barnes, K. R.; Kutikov, A.; Lippard, S. J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol., 2004, 11 (4), 557-564.
150. Muller, P.; Schroder, B.; Parkinson, J. A.; Kratochwil, N. A.; Coxall, R. A.; Parkin, A.; Parsons, S.; Sadler, P. J. Nucleotide cross-linking induced by photoreactions of platinum(IV)-azide complexes. Angew. Chem. Int. Ed., 2003, 42 (3), 335-339.
151. Schmid, W. F.; John, R. O.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Highly antiproliferative ruthenium(II) and osmium(II) arene complexes with paullone-derived Ligands. Organometallics, 2007, 26 (26), 6643-6652.
152. Meggers, E. Targeting proteins with metal complexes. Chem. Commun., 2009, (9), 1001-1010.
153. Becker, J. S.; Lobinski, R.; Becker, J. S. Metal imaging in non-denaturating 2D electrophoresis gels by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) for the detection of metalloproteins. Metallomics, 2009, 1 (4), 312-316.
154. Min, W.; Lu, S. J.; Chong, S. S.; Roy, R.; Holtom, G. R.; Xie, X. S. Imaging chromophores with undetectable fluorescence by stimulated emission microscopy. Nature, 2009, 461 (7267), 1105-1109.
155. rd ed.; Oxford University Press: New York, N.Y., 2005; p xiii, 649 p.
156. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M. P.; Bindoli, A.; Geldbach, T. J.; Marrone, A.; Re, N.; Hartinger, C. G.; Dyson, P. J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin b by antitumor ruthenium(II) arene compounds. J. Med. Chem., 2008, 51 (21), 6773-6781.
157. Deubel, D. V.; Lau, J. K.-C. In silico evolution of substrate selectivity: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin. Chem. Commun., 2006, (23), 2451-2453.
158. Dorcier, A.; Dyson, P. J.; Gossens, C.; Rothlisberger, U.; Scopelliti, R.; Tavernelli, I. Binding of organometallic ruthenium (II) and osmium(II) complexes to an oligonucleotide: a combined mass spectrometric and theoretical study. Organometallics, 2005, 24 (9), 2114-2123.